Isarna's ISTH0036 Shows Promise in Reducing Retinal Fibrosis in Phase 2 BETTER Trial
Isarna Therapeutics' antisense therapy ISTH0036, which blocks TGF-β2 production, demonstrated positive results in treating retinal fibrosis in wet AMD and DME patients at the ARVO 2025 Annual Meeting.
Antisense Oligonucleotide Therapies Advance in Genetic Medicine
Ionis Pharmaceuticals, a pioneer in antisense oligonucleotide (ASO) drugs, priced a $500 million IPO to fund clinical programs and commercial launches.
© Copyright 2025. All Rights Reserved by MedPath